Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: A cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa

Infectious Agents and Cancer

Volumn 6, Issue 1, 2011, Pages

  Maskew, Mhairi ^a   MacPhail, A ^a,b   Whitby, Denise ^c   Egger, Matthias ^d   Wallis, Carole L ^a   Fox, Matthew P ^a,e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b RIGHT TO CARE   (South Africa)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antiretroviral therapy; Kaposi sarcoma; Kaposi sarcoma herpes virus; resource poor setting

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BODY MASS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS-SECTIONAL STUDY; FEMALE; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SEROPREVALENCE; SOUTH AFRICA; TUBERCULOSIS; VIREMIA; VIRUS LOAD;

EID: 81155124436     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-6-22     Document Type: Article

References (53)

1. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. Hogg RS, Heath KV, Yip B, et al. JAMA 1998 279 450 4 10.1001/jama.279.6.450 9466638 (Pubitemid 28082255)
2. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. Jensen-Fangel S, Pedersen L, Pedersen C, et al. AIDS 2004 18 89 97 10.1097/00002030-200401020- 00011 15090834 (Pubitemid 38402322)
3. -2008 report on the global AIDS epidemic. UNAIDS, 2008 http://www.unaids.org/en/dataanalysis/epidemiology/ 2008reportontheglobalaidsepidemic/ Accessed August 2010
4. Part I: Cancer in Indigenous Africans - burden, distribution, and trends. Parkin DM, Sitas F, Chirenje M, et al. The lancet oncology 2008 9 683 92 10.1016/S1470-2045(08)70175-X 18598933 (Pubitemid 351878054)
5. The spectrum of human immunodeficiency virus associated cancers in a South African black population: results from a case-control study, 1995-2004. Stein L, Urban MI, O'Connell D, et al. International journal of cancer 2008 122 2260 5 10.1002/ijc.23391 (Pubitemid 351542329)
6. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Whitby D, Howard MR, Tenant-Flowers M, et al. Lancet 1995 346 799 802 10.1016/S0140-6736(95) 91619-9 7674745
7. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Cook-Mozaffari P, Newton R, Beral V, Burkitt DP, British journal of cancer 1998 78 1521 8 10.1038/bjc.1998.717 9836488 (Pubitemid 28517552)
8. Epidemiology of AIDS-related tumours in developed and developing countries. Del Maso L, Serraino D, Franceschi S, European Journal of Cancer 2001 37 1188 1201 10.1016/S0959-8049(01)00120-4 11423251 (Pubitemid 32553764)
9. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Jacobson LP, Yamashita TE, Detels R, Multicenter AIDS Cohort Study, et al. Journal of acquired immune deficiency syndromes 1999 21 Suppl 1 34 41 10430217
10. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Ledergerber B, Telenti A, Egger M, Swiss HIV Cohort Study, BMJ 1999 319 23 4 (Pubitemid 29304340)
11. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Mocroft A, Kirk O, Clumeck N, et al. Cancer 2004 100 2644 54 10.1002/cncr.20309 15197808 (Pubitemid 38715771)
12. World Health Organisation, WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children 2006 1 48
13. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. Anastos K, Shi Q, French AL, et al. Journal of acquired immune deficiency syndromes 2004 35 383 92 10.1097/00126334-200404010- 00008 15097155 (Pubitemid 38332799)
14. Determinants of clinical progression in antiretroviral naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. Bonnet F, Thiébaut R, Chêne G, et al. HIV medicine 2005 6 198 205 10.1111/j.1468-1293.2005.00290.x 15876287 (Pubitemid 40740337)
15. Disease Progression Among Untreated HIV-Infected Patients in South Ethiopia: Implications for Patient Care. Jerene D, Lindtjorn B, Journal of the International AIDS Society 2005 7 66 10.1186/1758-2652-7-3-66 19825131
16. Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. Lau B, Gange SJ, Phair JP, et al. Journal of acquired immune deficiency syndromes 2005 39 620 5 16044017 (Pubitemid 41098480)
17. Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS. Maas JJ, Dukers N, Krol A, et al. Journal of acquired immune deficiency syndromes and human retrovirology 1998 19 254 9 10.1097/00042560-199811010-00007 9803967
18. Usefulness of route of transmission, absolute CD8+ T-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4 + T-cell counts. Macías J, Leal M, Delgado J, et al. European journal of clinical microbiology & infectious diseases 2001 20 253 9 14757004 (Pubitemid 32477243)
19. Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting. Obirikorang C, Yeboah F, Journal of biomedical science 2009 16 102 10.1186/1423-0127-16-102 19922646
20. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Operskalski EA, Stram DO, Lee H, Transfusion Safety Study Group, et al. The Journal of infectious diseases 1995 172 648 55 10.1093/infdis/172.3.648 7658055
21. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action, Lancet 2000 355 1131 7 10791375
22. Predictors of disease progression in HIV infection: a review. Langford SE, Ananworanich J, Cooper D, AIDS research and therapy 2007 4 11 10.1186/1742-6405-4-11 17502001 (Pubitemid 47161536)
23. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. Cozzi Lepri A, Katzenstein TL, Ullum H, et al. AIDS 1998 12 1639 43 10.1097/00002030-199813000-00011 9764783 (Pubitemid 28418334)
24. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. Phillips A, Pezzotti P, AIDS 2004 18 51 8 15090829 (Pubitemid 38402317)
25. The CD4 lymphocyte count and risk of clinical progression. Phillips AN, Lundgren JD, Current opinion in HIV and AIDS 2006 1 43 9 10.1097/01.COH. 0000194106.12816.b1 19372783
26. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. Phillips AN, Gazzard B, Gilson R, et al. AIDS 2007 21 1717 21 17690569 (Pubitemid 47237558)
27. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. Bourboulia D, Aldam D, Lagos D, et al. AIDS 2004 18 485 93 10.1097/00002030-200402200-00015 15090801 (Pubitemid 38365876)
28. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. Wilkinson J, Cope A, Gill J, et al. Journal of virology 2002 76 2634 40 10.1128/JVI.76.6.2634-2640.2002 11861829 (Pubitemid 34184848)
29. National Antiretroviral Treatment Guidelines. National Department of Health, First 2004
30. Detection of antibodies to Kaposi's sarcoma associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. Mbisa GL, Miley W, Gamache CJ, et al. Journal of immunological methods 2010 356 39 46 10.1016/j.jim.2010.02.015 20211626
31. Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. Sanjosé S de, Marshall V, Sol J, et al. International journal of cancer 2002 98 155 8 10.1002/ijc.10190 (Pubitemid 34113433)
32. Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia. Klaskala W, Brayfield BP, Kankasa C, et al. Journal of medical virology 2005 75 93 100 10.1002/jmv.20242 15543582 (Pubitemid 39578795)
33. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. Adjei A, Armah HB, Gbagbo F, et al. BMC infectious diseases 2008 8 111 10.1186/1471-2334-8-111 18706107
34. Kaposi's Sarcoma Associated-Herpes Virus (KSHV) Seroprevalence in Pregnant Women in South Africa. Malope-Kgokong BI, Macphail P, Mbisa G, et al. Infectious agents and cancer 2010 5 14 10.1186/1750-9378-5-14 20807396
35. Antibodies against human herpesvirus 8 in black South African patients with cancer. Sitas F, Carrara H, Beral V, et al. The New England journal of medicine 1999 340 1863 71 10.1056/NEJM199906173402403 10369849 (Pubitemid 29272666)
36. Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. Smith Na, Sabin Ca, Gopal R, et al. The Journal of infectious diseases 1999 180 600 6 10.1086/314926 10438345 (Pubitemid 29411343)
37. Sexual transmission and the natural history of human herpesvirus 8 infection. Martin JN, Ganem DE, Osmond DH, et al. The New England journal of medicine 1998 338 948 54 10.1056/NEJM199804023381403 9521982 (Pubitemid 28152835)
38. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis. Schulz TF, Journal of Antimicrobial Chemotherapy 2000 45 15 27 10855768 (Pubitemid 30195570)
39. Detection of Kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. Mbulaiteye SM, Pfeiffer RM, Engels EA, et al. The Journal of infectious diseases 2004 190 1382 6 10.1086/424489 15378429 (Pubitemid 39332177)
40. Transmission of Kaposi sarcoma-associated herpesvirus between mothers and children in a South African population. Malope BI, Pfeiffer RM, Mbisa G, et al. Journal of acquired immune deficiency syndromes 2007 44 351 5 10.1097/QAI.0b013e31802f12ea 17195763 (Pubitemid 46328354)
41. Mucosal shedding of human herpesvirus 8 in men. Pauk J, Huang ML, Brodie SJ, et al. The New England journal of medicine 2000 343 1369 77 10.1056/NEJM200011093431904 11070101
42. No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. Malope BI, MacPhail P, Mbisa G, et al. AIDS 2008 22 519 26 10.1097/QAD.0b013e3282f46582 18301065 (Pubitemid 351317294)
43. Human herpesvirus 8 DNA load in the leukocytes correlates with the platelet counts in HIV type 1-infected individuals. Minami R, Yamamoto M, Takahama S, et al. AIDS research and human retroviruses 2009 25 1 8 10.1089/aid.2007.0260 19182916
44. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. El Amari EB, Toutous-Trellu L, Gayet-Ageron A, et al. AIDS 2008 22 1019 28 10.1097/QAD.0b013e3282fc9c03 18520345 (Pubitemid 351769740)
45. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. Campbell TB, Borok M, Gwanzura L, et al. AIDS 2000 14 2109 16 10.1097/00002030-200009290-00006 11061651
46. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Ogg GS, Jin X, Bonhoeffer S, et al. Science 1998 279 2103 6 10.1126/science.279.5359.2103 9516110 (Pubitemid 28196353)
47. Molecular virology and immunology of HIV infection. Chinen J, Shearer WT, The Journal of allergy and clinical immunology 2002 110 189 98 10.1067/mai.2002.126226 12170257
48. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? Blackard JT, Sherman KE, Journal of viral hepatitis 2008 15 323 30 10.1111/j.1365-2893.2008.00970.x 18208497 (Pubitemid 351473633)
49. Incidence of multiple Herpesvirus infection in HIV seropositive patients, a big concern for Eastern Indian scenario. Chakraborty N, Bhattacharyya S, De C, et al. Virology journal 2010 7 147 10.1186/1743-422X-7-147 20604948
50. Effects of multiple virus coinfections on disease progression in HIV-positive patients. Shieh B, Chang M-J, Ko W-C, et al. Intervirology 2003 46 105 13 10.1159/000069745 12684549 (Pubitemid 36407927)
51. Significance of variation within HIV, EBV, and KSHV subtypes. Stebbing J, Powles T, Nelson M, Bower M, Journal of the International Association of Physicians in AIDS Care 2006 5 93 102 10.1177/1545109706290171 16928877
52. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Caselli E, Galvan M, Cassai E, et al. Blood 2005 106 2790 7 10.1182/blood-2005- 04-1390 15976177 (Pubitemid 41510755)
53. No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients. Ait-Arkoub Z, Robert-Visse C, Calvez V, et al. AIDS 2003 17 1394 6 10.1097/00002030-200306130-00016 12799563 (Pubitemid 36819856)